yahoo.comAUG 231 min read$CAH

Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know

Cardinal Health's (CAH) Chief Legal Officer, Jessica L. Mayer, sold 29,436 shares at $236.19 each on August 18, totaling ~$7.0 million. Post-transaction, she holds 33,076 shares. The company has a $55.0 billion market cap and $254.2 billion TTM revenue. CFO and CIO also sold shares the same day. Management discussed 340B and IRA pricing pressures during the earnings call.

Original reporting

yahoo.com

Published Aug 23, 2026, 11:45 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 12:19 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know — source image — Source · yahoo.com

Decision brief

The 30-second read

$CAHBearishLow

Why it matters

The insider sale adds a modest negative catalyst, but the company's fundamentals and recent earnings guidance remain primary drivers.

Market read

Insider sales by senior executives can influence short‑term sentiment for a large healthcare distributor.

What to watch

Other executives also sold shares, suggesting a broader pattern rather than a single red flag.

Relevance 5/10Novelty 6/10Timing: post‑transaction August 18 filing reported August 23

Background

Cardinal Health is a large, integrated healthcare services provider with a market cap of $55 billion.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHBearishMedium confidence

Context

Chief Legal Officer Jessica L. Mayer sold 29,436 shares of Cardinal Health for about $7 million, reducing her ownership to 0.01% after the transaction.

Expected impact

Possible short‑term downside pressure as investors digest the insider sale.

Evidence & confidence

C‑level insider sales are closely watched; the $7 M disposition is sizable for a company of this scale and may trigger sell‑offs.

Market effects

Sector

May raise questions about governance and valuation in the healthcare distribution sector.

Regional

Limited to U.S. healthcare services investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine diversification move unrelated to company fundamentals.

Key entities

executive
Jessica L. Mayer
Chief Legal Officer of Cardinal Health
executive
Aaron Alt
Chief Financial Officer of Cardinal Health, also sold shares

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min